Drugmakers slash prices in China to get on reimbursement list
Share:
BEIJING/SHANGHAI (Reuters) - Drugmakers including Roche and Novartis' have agreed to cut the prices of some of their newest drugs by an average of 61% in China in order to get on a national reimbursement scheme list, regulators said.Addition to the list is likely to boost sales volume by opening up markets in smaller and less-affluent Chinese cities, but some industry insiders have cautioned that only offering deep price cuts in China could spark criticism of the drugmakers in other markets...